Publications by authors named "Teruo Inamoto"
Background: Androgen-receptor signaling inhibitors (ARSIs) become the new standard of care for metastatic hormone-sensitive prostate cancer (mHSPC). It is unknown whether time to castration resistance (TTCR), when using the first-line ARSIs, offers predictive value in mHSPC. We sought to assess the clinical outcomes for mHSPC patients treated with first-line ARSIs focusing on the TTCR.
View Article and Find Full Text PDFHyper progressive disease (HPD) is a paradoxical phenomenon characterized by accelerated tumor growth following treatment with immune checkpoint inhibitors. However, the pathogenic causality and its predictor remain unknown. We herein report a fatal case of HPD in a 50-year-old man with metastatic bladder cancer.
View Article and Find Full Text PDFBackground: Enfortumab vedotin (EV), an antibody-drug conjugate that targets Nectin-4, is used for patients with metastatic urothelial carcinoma who have experienced progression on platinum-based chemotherapy and checkpoint inhibitors. Despite the widespread use of the drug, evidence remains scarce regarding clinical indicators that can predict the response to EV treatment.
Objective: We aimed to explore the predictive value of clinical indicators derived from peripheral blood tests for treatment responses to EV.
Article Synopsis
- - Enfortumab vedotin (EV) is an antibody-drug conjugate used for patients with metastatic urothelial carcinoma (mUC) who have progressed on checkpoint inhibitors (CPIs); however, there's limited evidence comparing EV directly with re-challenging chemotherapy in real-world settings.
- - In a study of 350 mUC patients, those treated with EV showed an objective response rate (ORR) of 48% and a median overall survival (OS) of 29 months, compared to 14 months for re-challenging chemotherapy and 8 months for continuing CPIs beyond progression.
- - While there was no significant difference in overall survival or progression-free survival between EV and re-challenging chemotherapy, the duration
Background: Living kidney transplant donors are classified as stage 3 chronic kidney disease after kidney donation. For this reason, we provide daily lifestyle guidance, such as blood pressure and weight management before surgery, and dietary counseling focused on salt restriction. We emphasize providing lifestyle guidance after kidney donation.
View Article and Find Full Text PDFArticle Synopsis
- - Bladder cancer (BC) patients can experience shrinkage due to radiation-induced fibrosis, and specific microRNAs (miRNAs) are linked to this injury and overall survival.
- - In a study of three Japanese BC patients, certain miRNAs (such as hsa-miR-130a and hsa-miR-200c) were highly expressed in those with fibrotic bladder shrinkage compared to patients with intact bladder function.
- - Analysis of 409 BC patients revealed that high expression of specific miRNAs correlated with significantly longer median survival, indicating a potential role for these miRNAs in predicting patient outcomes and targeting profibrotic cytokines.
Article Synopsis
- There is currently limited understanding of how alterations in fibroblast growth factor receptor 3 (FGFR3) affect bladder cancer (BLCA) and its tumor microenvironment (TME).
- A study involving multi-omics analysis of BLCA tissues showed that aFGFR3 alterations are found in 44% of non-muscle invasive cases and 15% of muscle-invasive cases, affecting their immune response and tumor characteristics.
- Notably, the LumP subtype in aFGFR3 cases responded significantly better to checkpoint inhibitors compared to their intact FGFR3 counterparts, suggesting that FGFR3 status influences treatment outcomes in bladder cancer.
Purpose: This study investigates the utility of ureteroscopic surgery (URS) as an alternative to radical nephroureterectomy (RNU) in managing upper tract urothelial carcinoma (UTUC), with a focus on survival outcomes and re-evaluation of current the European Association of Urology guidelines criteria.
Methods: We conducted a retrospective, multi-institutional review of 143 UTUC patients treated with URS (n = 35) or RNU (n = 108). Clinicopathological factors were analyzed, and survival outcomes were assessed using Kaplan-Meier analysis and Cox proportional-hazards models.
Renomedullary interstitial cell tumor (RMICT), referred to as a medullary fibroma, is almost always asymptomatic and incidentally identified either at autopsy or upon resection of the kidney for other reasons. Although a few cases of RMICTs that are large in size and clinically symptomatic have been reported, there are few reports of RMICTs contrasting imaging findings with pathological findings. In this report, we describe a relatively large RMICT case of 3 cm in size, focusing on the radiologic-pathologic correlation.
View Article and Find Full Text PDFBackground: Immune checkpoint inhibitors can cause various immune-related adverse events (irAEs). This study aimed to evaluate the association between the incidence of irAEs and oncological outcomes of metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab as first-line therapy.
Patients And Methods: We retrospectively analyzed data from 69 patients with mRCC treated with nivolumab plus ipilimumab as first-line therapy between September 2018 and September 2021 at 4 institutions.
Article Synopsis
- The study aimed to identify simple indicators from daily clinical practice that can predict the objective response to pembrolizumab in metastatic urothelial carcinoma patients, which is known for leading to better survival outcomes.
- The analysis of 220 patients revealed that changes in the neutrophil-lymphocyte ratio (NLR) and the presence of liver metastasis were significant predictors of treatment response.
- The risk model created categorized patients into favorable, intermediate, and poor risk groups, correlating with different objective response rates and overall survival outcomes, suggesting that those in the "poor risk" category might benefit from alternative therapies.
Article Synopsis
- * In a study of 50 platinum-refractory mUC patients, 24% had TLS, but no significant difference in NLR between groups with or without TLS was found.
- * The research showed that lower NLR patients with TLS had longer overall survival and progression-free survival, while these benefits were not seen in higher NLR patients, suggesting that the presence of TLS may correlate with better treatment outcomes in specific patient groups.
Background: There is little evidence of abiraterone acetate (AA) plus prednisone for patients with non-metastatic castration-resistant prostate cancer (nmCRPC). In this study, we conducted a comparative analysis of real-world survival outcomes between AA plus prednisone and enzalutamide (Enz) in patients with nmCRPC, utilizing our consortium dataset.
Materials And Methods: The clinical records of 133 nmCRPC patients treated with first-line Enz or AA plus prednisone were analyzed.
Objective: To determine the safety of cabazitaxel and predictors of severe neutropenia caused by cabazitaxel in a patient population that includes those with comorbidities.
Materials And Methods: Of 42 prostate cancer patients treated with cabazitaxel at Osaka Medical and Pharmaceutical University Hospital between September 2014 and June 2022, 33 were included in this study, whereas 6 patients who were outpatients and 3 who were discharged early within 7 days upon patient request were excluded. Logistic regression analysis was used to examine predictors of severe neutropenia.
Article Synopsis
- - This study evaluated the effectiveness of nivolumab monotherapy for metastatic renal cell carcinoma (mRCC) in Japanese patients over a 36-month period, focusing on overall survival, progression-free survival, and response rates.
- - Out of 208 patients, about 12% remained on nivolumab treatment after 36 months, with a significant portion discontinuing due to disease progression; the overall survival rate at 36 months was 54.3%.
- - The findings suggest that nivolumab offers a notable survival advantage, especially for patients with favorable risk, and highlights the benefits of continuing treatment after nivolumab with other therapies like VEGF receptor-TKIs.
Background: Sodium retention causes post-transplant hypertension, and sodium restriction is recommended in kidney transplantation recipients. We investigated the changes in salt intake and age-specific differences in salt intake over the post-transplant periods and considered what guidance is important for salt reduction tailored to individual recipients.
Methods: We calculated salt intake for 38 recipients who underwent kidney transplantation from August 2013 to August 2018 using Tanaka's equation and extracted their blood pressure (BP) levels.
Article Synopsis
- The study analyzed the effectiveness of pembrolizumab in Japanese patients with metastatic urothelial carcinoma, focusing on the time it takes to see a response to the treatment.
- Results indicated that the objective response rate was 27.1%, with a median time to response of 2.4 months and the best response occurring after 3.1 months.
- The findings suggest that evaluating treatment response at later stages (like 8 months) is more predictive of overall survival, implying that doctors might benefit from waiting until treatment is closer to completion to assess effectiveness.
Article Synopsis
- The study compares the effectiveness of intra-arterial (IA) cisplatin infusion versus intravenous (IV) infusion in targeting pelvic lymph nodes in a rat model, aiming to improve treatment outcomes for bladder cancer.
- Results showed that IA infusion resulted in significantly higher concentrations of cisplatin in the bladder and lymphatic tissue compared to the IV infusion, suggesting a more localized delivery of the drug.
- Findings indicate that IA administration could have a promising role in treating patients with node-positive bladder cancer due to its ability to concentrate the drug effectively in critical areas.
Article Synopsis
- The study evaluated factors influencing overall survival (OS) in 101 advanced urothelial cancer (UC) patients undergoing sequential therapy, consisting of platinum-based chemotherapy and pembrolizumab.
- Key findings revealed that progression-free survival with pembrolizumab (PFS with pembrolizumab) and second progression-free survival (PFS2) were significant indicators of OS, with PFS2 being the stronger predictor.
- The research highlights the importance of considering patients’ baseline performance status and neutrophil-to-lymphocyte ratio when planning treatment, particularly for those with higher risks before starting first-line chemotherapy.
Article Synopsis
- Pembrolizumab is a key treatment for metastatic urothelial carcinoma (mUC) but its effectiveness varies among patients; this study aims to explore how palliative radiation may enhance its survival benefits.
- A review of a dataset involving 235 mUC patients showed that those who received concurrent palliative radiation with pembrolizumab had significantly longer overall survival (OS) compared to those who did not or those who had radiation before starting pembrolizumab.
- After adjusting for potential biases, patients treated with concurrent radiation had a median OS of 29 months versus 13 months for those without it, suggesting that combining these treatments might improve outcomes for mUC patients.
Serum C-reactive protein (CRP) is known to be a biomarker for systemic inflammatory reactions. In the present study, we sought to measure the predictive value of serum CRP level for metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab and nivolumab using our real-world clinical dataset including non-clear cell RCC (nccRCC). The clinical record of patients who underwent the first-line ipilimumab plus nivolumab treatment for mRCC including ccRCC and nccRCC from 2018 to 2021 was retrospectively analyzed.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the clinical benefits of administering chemotherapy after pembrolizumab treatment in patients with metastatic urothelial carcinoma, focusing on whether it can restore sensitivity to platinum-based drugs.
- Out of 236 patients who received pembrolizumab, 105 were analyzed for their survival outcomes, comparing those who continued with pembrolizumab versus those who received re-challenging chemotherapy after showing disease progression.
- Results indicated that patients who received re-challenging chemotherapy had a significantly longer median overall survival (13.9 months) compared to those who continued with pembrolizumab (5.8 months), suggesting the potential effectiveness of this treatment strategy.
Background: Site-specific postoperative risk models for localized upper tract urothelial carcinoma (UTUC) are unavailable.
Objective: To create specific risk models for renal pelvic urothelial carcinoma (RPUC) and ureteral urothelial carcinoma (UUC), and to compare the predictive accuracy with the overall UTUC risk model.
Design Setting And Participants: A multi-institutional database retrospective study of 1917 UTUC patients who underwent radical nephroureterectomy (RNU) between 2000 and 2018 was conducted.
Patients with end-stage renal disease (ESRD) have a low nutritional status and a high mortality risk. The geriatric nutritional risk index (GNRI) is a predictive marker of malnutrition. However, the association between unplanned hemodialysis (HD) and GNRI with mortality remains unclear.
View Article and Find Full Text PDFPurpose: Most patients with metastatic urothelial carcinoma experience no objective response to pembrolizumab and have poor overall survival (OS). Here, we investigated the prognostic value of fluctuation in the neutrophil-lymphocyte ratio (NLR) at 6 weeks of pembrolizumab treatment, focusing on its association with the achievement of objective response.
Materials And Methods: The clinical records of 177 metastatic urothelial carcinoma patients treated with pembrolizumab were retrospectively analyzed.